Selected research
Industry Research
Bipolar Disorder Medications Industry Research Report 2026
Market perspective
The global Bipolar Disorder Medications market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Bipolar Disorder Medications is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Bipolar Disorder Medications is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Bipolar Disorder Medications is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Bipolar Disorder Medications include Janssen Pharmaceuticals, Johnson & Johnson, Novartis AG, Eli Lily and Company, Pfizer Inc., Glaxo SmithKline (GSK), AbbVie Inc., Validus Pharmaceuticals LLC. and Otsuka Holdings Co. Ltd, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Bipolar Disorder Medications market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Bipolar Disorder Medications Market by Company
Janssen Pharmaceuticals
Johnson & Johnson
Novartis AG
Eli Lily and Company
Pfizer Inc.
Glaxo SmithKline (GSK)
AbbVie Inc.
Validus Pharmaceuticals LLC.
Otsuka Holdings Co. Ltd
H. Lundbeck A/S
Gedeon Richter PLC.
Bristol Myers Squibb
Astellas Pharma Inc
Bipolar Disorder Medications Segment by Type
Anti-Anxiety Drugs
Anticonvulsants
Antipsychotic Drugs
Antidepressant Drugs
Mood Stabilizers
Bipolar Disorder Medications Segment by Application
Hospital
Clinic
Bipolar Disorder Medications Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Bipolar Disorder Medications market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Bipolar Disorder Medications and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Bipolar Disorder Medications.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Bipolar Disorder Medications manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Bipolar Disorder Medications by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Bipolar Disorder Medications in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Anti-Anxiety Drugs
- Anticonvulsants
- Antipsychotic Drugs
- Antidepressant Drugs
- Mood Stabilizers
Applications
- Hospital
- Clinic
Companies covered
- Janssen Pharmaceuticals
- Johnson & Johnson
- Novartis AG
- Eli Lily and Company
- Pfizer Inc.
- Glaxo SmithKline (GSK)
- AbbVie Inc.
- Validus Pharmaceuticals LLC.
- Otsuka Holdings Co. Ltd
- H. Lundbeck A/S
- Gedeon Richter PLC.
- Bristol Myers Squibb
- Astellas Pharma Inc
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Bipolar Disorder Medications Market Size (2021-2032)
- 2.2.2 Global Bipolar Disorder Medications Sales (2021-2032)
- 2.2.3 Global Bipolar Disorder Medications Market Average Price (2021-2032)
- 2.3 Bipolar Disorder Medications by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Anti-Anxiety Drugs
- 2.3.3 Anticonvulsants
- 2.3.4 Antipsychotic Drugs
- 2.3.5 Antidepressant Drugs
- 2.3.6 Mood Stabilizers
- 2.4 Bipolar Disorder Medications by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Bipolar Disorder Medications Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Bipolar Disorder Medications Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Bipolar Disorder Medications Revenue of Manufacturers (2021-2026)
- 3.4 Global Bipolar Disorder Medications Average Price by Manufacturers (2021-2026)
- 3.5 Global Bipolar Disorder Medications Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Bipolar Disorder Medications, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Bipolar Disorder Medications, Product Type & Application
- 3.8 Global Manufacturers of Bipolar Disorder Medications, Established Date
- 3.9 Global Bipolar Disorder Medications Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Janssen Pharmaceuticals
- 4.1.1 Janssen Pharmaceuticals Company Information
- 4.1.2 Janssen Pharmaceuticals Business Overview
- 4.1.3 Janssen Pharmaceuticals Bipolar Disorder Medications Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Janssen Pharmaceuticals Bipolar Disorder Medications Product Portfolio
- 4.1.5 Janssen Pharmaceuticals Recent Developments
- 4.2 Johnson & Johnson
- 4.2.1 Johnson & Johnson Company Information
- 4.2.2 Johnson & Johnson Business Overview
- 4.2.3 Johnson & Johnson Bipolar Disorder Medications Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Johnson & Johnson Bipolar Disorder Medications Product Portfolio
- 4.2.5 Johnson & Johnson Recent Developments
- 4.3 Novartis AG
- 4.3.1 Novartis AG Company Information
- 4.3.2 Novartis AG Business Overview
- 4.3.3 Novartis AG Bipolar Disorder Medications Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Novartis AG Bipolar Disorder Medications Product Portfolio
- 4.3.5 Novartis AG Recent Developments
- 4.4 Eli Lily and Company
- 4.4.1 Eli Lily and Company Company Information
- 4.4.2 Eli Lily and Company Business Overview
- 4.4.3 Eli Lily and Company Bipolar Disorder Medications Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Eli Lily and Company Bipolar Disorder Medications Product Portfolio
- 4.4.5 Eli Lily and Company Recent Developments
- 4.5 Pfizer Inc.
- 4.5.1 Pfizer Inc. Company Information
- 4.5.2 Pfizer Inc. Business Overview
- 4.5.3 Pfizer Inc. Bipolar Disorder Medications Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Pfizer Inc. Bipolar Disorder Medications Product Portfolio
- 4.5.5 Pfizer Inc. Recent Developments
- 4.6 Glaxo SmithKline (GSK)
- 4.6.1 Glaxo SmithKline (GSK) Company Information
- 4.6.2 Glaxo SmithKline (GSK) Business Overview
- 4.6.3 Glaxo SmithKline (GSK) Bipolar Disorder Medications Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Glaxo SmithKline (GSK) Bipolar Disorder Medications Product Portfolio
- 4.6.5 Glaxo SmithKline (GSK) Recent Developments
- 4.7 AbbVie Inc.
- 4.7.1 AbbVie Inc. Company Information
- 4.7.2 AbbVie Inc. Business Overview
- 4.7.3 AbbVie Inc. Bipolar Disorder Medications Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 AbbVie Inc. Bipolar Disorder Medications Product Portfolio
- 4.7.5 AbbVie Inc. Recent Developments
- 4.8 Validus Pharmaceuticals LLC.
- 4.8.1 Validus Pharmaceuticals LLC. Company Information
- 4.8.2 Validus Pharmaceuticals LLC. Business Overview
- 4.8.3 Validus Pharmaceuticals LLC. Bipolar Disorder Medications Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Validus Pharmaceuticals LLC. Bipolar Disorder Medications Product Portfolio
- 4.8.5 Validus Pharmaceuticals LLC. Recent Developments
- 4.9 Otsuka Holdings Co. Ltd
- 4.9.1 Otsuka Holdings Co. Ltd Company Information
- 4.9.2 Otsuka Holdings Co. Ltd Business Overview
- 4.9.3 Otsuka Holdings Co. Ltd Bipolar Disorder Medications Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Otsuka Holdings Co. Ltd Bipolar Disorder Medications Product Portfolio
- 4.9.5 Otsuka Holdings Co. Ltd Recent Developments
- 4.10 H. Lundbeck A/S
- 4.10.1 H. Lundbeck A/S Company Information
- 4.10.2 H. Lundbeck A/S Business Overview
- 4.10.3 H. Lundbeck A/S Bipolar Disorder Medications Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 H. Lundbeck A/S Bipolar Disorder Medications Product Portfolio
- 4.10.5 H. Lundbeck A/S Recent Developments
- 4.11 Gedeon Richter PLC.
- 4.11.1 Gedeon Richter PLC. Company Information
- 4.11.2 Gedeon Richter PLC. Business Overview
- 4.11.3 Gedeon Richter PLC. Bipolar Disorder Medications Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Gedeon Richter PLC. Bipolar Disorder Medications Product Portfolio
- 4.11.5 Gedeon Richter PLC. Recent Developments
- 4.12 Bristol Myers Squibb
- 4.12.1 Bristol Myers Squibb Company Information
- 4.12.2 Bristol Myers Squibb Business Overview
- 4.12.3 Bristol Myers Squibb Bipolar Disorder Medications Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Bristol Myers Squibb Bipolar Disorder Medications Product Portfolio
- 4.12.5 Bristol Myers Squibb Recent Developments
- 4.13 Astellas Pharma Inc
- 4.13.1 Astellas Pharma Inc Company Information
- 4.13.2 Astellas Pharma Inc Business Overview
- 4.13.3 Astellas Pharma Inc Bipolar Disorder Medications Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Astellas Pharma Inc Bipolar Disorder Medications Product Portfolio
- 4.13.5 Astellas Pharma Inc Recent Developments
5 Global Bipolar Disorder Medications Market Scenario by Region
- 5.1 Global Bipolar Disorder Medications Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Bipolar Disorder Medications Sales by Region: 2021-2032
- 5.2.1 Global Bipolar Disorder Medications Sales by Region: 2021-2026
- 5.2.2 Global Bipolar Disorder Medications Sales by Region: 2027-2032
- 5.3 Global Bipolar Disorder Medications Revenue by Region: 2021-2032
- 5.3.1 Global Bipolar Disorder Medications Revenue by Region: 2021-2026
- 5.3.2 Global Bipolar Disorder Medications Revenue by Region: 2027-2032
- 5.4 North America Bipolar Disorder Medications Market Facts & Figures by Country
- 5.4.1 North America Bipolar Disorder Medications Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Bipolar Disorder Medications Sales by Country (2021-2032)
- 5.4.3 North America Bipolar Disorder Medications Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Bipolar Disorder Medications Market Facts & Figures by Country
- 5.5.1 Europe Bipolar Disorder Medications Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Bipolar Disorder Medications Sales by Country (2021-2032)
- 5.5.3 Europe Bipolar Disorder Medications Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Bipolar Disorder Medications Market Facts & Figures by Country
- 5.6.1 Asia Pacific Bipolar Disorder Medications Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Bipolar Disorder Medications Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Bipolar Disorder Medications Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Bipolar Disorder Medications Market Facts & Figures by Country
- 5.7.1 South America Bipolar Disorder Medications Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Bipolar Disorder Medications Sales by Country (2021-2032)
- 5.7.3 South America Bipolar Disorder Medications Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Bipolar Disorder Medications Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Bipolar Disorder Medications Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Bipolar Disorder Medications Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Bipolar Disorder Medications Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Bipolar Disorder Medications Sales by Type (2021-2032)
- 6.1.1 Global Bipolar Disorder Medications Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Bipolar Disorder Medications Sales Market Share by Type (2021-2032)
- 6.2 Global Bipolar Disorder Medications Revenue by Type (2021-2032)
- 6.2.1 Global Bipolar Disorder Medications Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Bipolar Disorder Medications Revenue Market Share by Type (2021-2032)
- 6.3 Global Bipolar Disorder Medications Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Bipolar Disorder Medications Sales by Application (2021-2032)
- 7.1.1 Global Bipolar Disorder Medications Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Bipolar Disorder Medications Sales Market Share by Application (2021-2032)
- 7.2 Global Bipolar Disorder Medications Revenue by Application (2021-2032)
- 7.2.1 Global Bipolar Disorder Medications Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Bipolar Disorder Medications Revenue Market Share by Application (2021-2032)
- 7.3 Global Bipolar Disorder Medications Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Bipolar Disorder Medications Value Chain Analysis
- 8.1.1 Bipolar Disorder Medications Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Bipolar Disorder Medications Production Mode & Process
- 8.2 Bipolar Disorder Medications Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Bipolar Disorder Medications Distributors
- 8.2.3 Bipolar Disorder Medications Customers
9 Global Bipolar Disorder Medications Analyzing Market Dynamics
- 9.1 Bipolar Disorder Medications Industry Trends
- 9.2 Bipolar Disorder Medications Industry Drivers
- 9.3 Bipolar Disorder Medications Industry Opportunities and Challenges
- 9.4 Bipolar Disorder Medications Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst